| Similar Articles |
|---|
 |
The Motley Fool
February 9, 2006
Jason Mac Gurn |
RNA: Rule Breaker Nucleic Acid Investors, new RNA-based technologies may be the next revolution in biopharmaceuticals. ISIS Pharmaceuticals... Sirna Therapeutics... Alnylam Pharmaceuticals...   |
The Motley Fool
October 5, 2006
Ralph Casale |
RNAi: Nobel Prize-Winning Biotechnology While drugs based on RNAi knockdown technology may have the potential to become the next big thing in biotechnology, they are still a long way from becoming FDA-approved marketable entities. But it's never too soon to start keeping an eye on the future. Investors, take note. |
Bio-IT World
December 15, 2004
Zachary Zimmerman |
Silence Is Golden Life Science Insights believes that RNAi therapeutics will dramatically affect the pharmaceutical and healthcare industries, becoming the next major class of therapeutics, joining small molecules, proteins, and monoclonal antibodies. |
The Motley Fool
November 6, 2006
Ralph Casale |
Validation for a Biotechnology Firm? How Merck's bid to buy a competitor could affect Alnylam Pharmaceuticals. With the recent run-up in share price due to the Merck offer for Sirna, investors should wait for a better price before speculating on Alnylam. |
Bio-IT World
December 15, 2004
Nancy Weil |
Running Interference The revolution in RNA interference has galvanized basic research. Now, some biopharmas are pushing the technology from the laboratory to the clinic. |
Bio-IT World
November 2006
Kevin Davies |
Merck's $1.1 Billion Bet on RNAi As if the 2006 Nobel Prize in Medicine or Physiology wasn't validation enough, Merck's acquisition of biotech firm Sirna for $1.1 billion last month offered evidence of the commercial implications of RNA interference gene-silencing technology. |
The Motley Fool
February 26, 2010
Brian Orelli |
A Risky Deal, but at Least It's Cheap Glaxo licenses a preclinical compound from Regulus. |
The Motley Fool
July 11, 2007
Brian Orelli |
Everybody Loves RNAi Roche is the latest firm to (over)pay for the hottest new drug technology. Alnylam announced that it licensed some of its intellectual property to Roche for $331 million. Investors, take note. |
The Motley Fool
November 30, 2010
Brian Orelli |
RNAi Is On Sale The novel technology looks more promising at these prices. |
The Motley Fool
September 20, 2007
Brian Orelli |
A Pharma Divorce, and Good Riddance Merck and Alnylam call it quits. The only real question is why the two didn't end the partnership months ago. What will it mean to investors? |
The Motley Fool
September 24, 2010
Brian Orelli |
So Long and Thanks for All the Drug Candidates Alnylam and Novartis end their five-year partnership. |
The Motley Fool
December 29, 2006
Brian Lawler |
Sirna Decides to Take the Cash and Run Shareholders vote to approve Merck's buyout offer. Investors in shares of Merck really have to trust management to have done its due diligence on Sirna and to have faith in its technology. |
Bio-IT World
July 15, 2003
Malorye Branca |
Silence Is Golden RNA interference's scientific, therapeutic, and economic potential is unquestionable, but some sticky questions still remain. |
The Motley Fool
May 18, 2007
Mike Havrilla |
Ample Opportunities for Alnylam The biotech's RNAi pipeline and cutting-edge technology make it a prime takeover candidate. Investors, take note. |
The Motley Fool
September 28, 2007
Brian Orelli |
RNAi Doesn't Kill Mice After All From Merck, to AstraZeneca, to Novartis, big pharma continues to pump hundreds of millions of dollars into unproven RNAi technology. Investors, take note. |
The Motley Fool
January 31, 2011
Brian Orelli |
Time to Buy Into Stem Cells? New developments bring this analyst a step closer to opening his wallet. |
The Motley Fool
November 13, 2006
Jack Uldrich |
Arrowhead: A Long-Term RNAi Play? Its majority stake in Calando Pharmaceuticals could pay dividends. Investors would be wise to continue to watch this company and wait until clinical trials have advanced to a more mature stage before considering an investment. |
BusinessWeek
February 26, 2007
Gene G. Marcial |
CytRx Can 'Silence' Genes That Cause Disease Since October, shares of CytRx have more than doubled as investors zeroed in on its RNA interference technology that targets diabetes, obesity, and ALS. |
Bio-IT World
June 2005
Nancy Weil |
Dharmacon Signs Library Deal The biopharma is providing its genome-wide short-interfering RNA (siRNA) library to Millennium Pharmaceuticals. This is the first commercial siRNA collection that targets genes across the entire human genome, encompassing some 22,000 genes. |
The Motley Fool
September 10, 2007
Brian Orelli |
Double Your RNA Pleasure Alnylam and ISIS join together to work on microRNAs. Their joint venture, called Regulus Therapeutics, combines their intellectual property in an effort to advance this new technology. Investors should take note. |
Bio-IT World
December 15, 2004
David A. Bumcrot |
Identifying RNAi Drug Candidates Breakthroughs in understanding RNA's extensive role in essential cellular processes have opened up the potential for a whole new class of drugs based on RNAi. |
Managed Care
November 2003
Thomas Morrow |
Making Sense of Antisense and Interference Treatments that interfere with protein synthesis at the cellular level will soon be debated in medical policy committee meetings. |
Chemistry World
July 2010
Hayley Birch |
Special Report: Health breakthroughs of the decade New discoveries have been made with cancer vaccines, genomics, statin drugs, allosteric modulators, and RNA interference during the last decade. |
The Motley Fool
May 28, 2008
Brian Orelli |
A Partnership of Habitual Deal Makers A partnership between these two companies gives Alnylam another $150 million to pad its coffers with and Takeda a call option on an unproven but promising set of drugs. |
The Motley Fool
August 1, 2007
Brian Orelli |
RNAi Gets Pumped Up Is a collaboration between RNAi expert Alnylam Pharmaceuticals and medical-device maker Medtronic something investors can endorse? |
Chemistry World
March 21, 2010
Simon Hadlington |
Nanoparticles successfully deliver RNA interference in cancer patients The system aims to exploit the phenomenon of RNA interference, where short sequences of double-stranded RNA, called small interfering RNA or siRNA, can trigger the disruption of the manufacture of certain proteins in a cell. |
Bio-IT World
Jul/Aug 2006 |
News Blast Health Solutions... Rna Interference... HIV Triple Combo... |
Bio-IT World
March 2006 |
News Blast Merck/Phase Forward... Curbing a Pandemic... Focused Trials... Collaboration... |
Bio-IT World
November 2005
G. Steven Burrill |
Biotech Posts Strong Third Quarter Despite overall subpar numbers in September, as compared with the previous four months, this was another excellent quarter for biotech... A good quarter for collaborations... IPO windows open slowly... Biotech still attractive for big pharmaceuticals... |
Chemistry World
April 28, 2008
Victoria Gill |
Gene silencing gets fat A team of researchers in the US has developed fat-like nanoparticles that can carry fragments of RNA into cells, bring treatments based on gene silencing a step closer. |
Pharmaceutical Executive
July 30, 2007 |
Tomorrow's Drugs A look at the seven top therapies and technologies vying to deliver the next generation of drugs. |
The Motley Fool
February 28, 2011
Brian D. Pacampara |
Next-Generation Drug Technologies Battle It Out Alnylam and Sangamo BioSciences have different ways to manipulate proteins to fight disease. |
The Motley Fool
September 8, 2006
Ralph Casale |
Genta's Down, but Is It Out? An FDA advisory committee voted not to recommend Genta's lead drug, Genasense, for approval. The news has knocked Genta's stock down by nearly two-thirds over the past week. |
The Motley Fool
November 30, 2010
Brian Orelli |
A Witty Response to Pharma's R&D Dilemma According to GlaxoSmithKline CEO Andrew Witty, the pharmaceutical industry is a mess. That's the basic gist of his opinion piece in The Economist. |
The Motley Fool
January 9, 2009
Brian Orelli |
Alnylam Holds Hands With a New Fella Is big pharma turning up its nose at RNAi drugs? |
Chemistry World
June 19, 2015
Rebecca Trager |
Alnylam accuses Dicerna of stealing trade secrets The US biopharmaceutical company Alnylam has filed a 'trade secret misappropriation' lawsuit against fellow Cambridge-based firm Dicerna. |
Bio-IT World
December 15, 2004
William Marshall |
Applications of RNAi RNA interference is a highly coordinated gene regulatory mechanism that appears to be highly conserved across all metazoans studied thus far. |
Chemistry World
June 12, 2014
Philli Broadwith |
Merck & Co bolsters hepatitis C pipeline with Idenix acquisition US drug firm Merck & Co has agreed to buy hepatitis C specialist Idenix for $3.85 billion. |
Pharmaceutical Executive
April 1, 2006
Patrick Clinton |
Deal Making: Who's Coming to the Table Noteworthy license deals and alliances in the pharmaceutical industry. |
Bio-IT World
November 2005
Robert M. Frederickson |
Innovations in Interference RNAi has moved from phenomenon to promising drug in less than five years, but it also has potential to be a tool used in drug discovery. |
BusinessWeek
January 29, 2007
Arlene Weintraub |
More Merger Mania Ahead For Pharma The scramble for new drugs is keeping companies on the prowl. |
The Motley Fool
February 29, 2008
Brian Orelli |
RNAi Works -- Maybe Alnylam presents the first proof of concept that RNAi works in humans, but where's the proof that it cures a disease? |
The Motley Fool
October 14, 2005
Jack Uldrich |
A TINY Alternative in Nanotech Arrowhead Research offers individual investors who are looking to profit from nanotechnology an alternative to Harris & Harris. |
The Motley Fool
January 3, 2005
Rich Duprey |
Eying Profits in Eye Sight Macular degeneration is proving to be a field with eye-popping potential. Manufactured by Pfizer and Eyetech, a tiny biotech that went public early last year, Macugen was recently approved by the FDA. |
Chemistry World
November 1, 2011
Sarah Houlton |
A Shot in the Arm for Drugs for Neglected Diseases A new consortium of public and private sector partners has been launched by the World Intellectual Property Organization. Its aim is to share intellectual property that may help find drugs for malaria, tuberculosis and other neglected tropical diseases. |
Bio-IT World
October 2006 |
Briefs Kovac Joins Burrill... RNAi Nobel Prize... Hooray for Hood... ArQule Next... Initiative Accelerated... |
The Motley Fool
June 9, 2009
Brian Orelli |
Alnylam Lays Down a Sacrifice Bunt RNAi is still an unproven technology, and there's plenty of chances for it to strike out. |
The Motley Fool
November 10, 2005
W.D. Crotty |
Portfolio Pain Relief Pain Therapeutics announces a significant development deal with King Pharmaceuticals. The company's stock is the largest percentage gainer on the Nasdaq -- up 48.9%. |
Pharmaceutical Executive
October 1, 2008 |
The other half of an HIV mystery is solved When HIV infects a human immune cell, which of the cell's own genes play a role? |
Chemistry World
September 26, 2006
Fiona Case |
Synchronised Delivery for DNA and Drugs Polymer capsules that can simultaneously deliver drug molecules and DNA into a cell could boost the power of cancer treatments. |
